AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RMD

Farrell Michael J. sold $1.2M of RMD

Farrell Michael J. (Chairman and CEO) sold 4,993 shares of RESMED INC (RMD) at $235.35 ($1.18M total) on 2026-11-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Farrell Michael J.
Published Nov 12, 2026, 11:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RMD
Neutral
medium confidence
Mentioned
$RMD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RMDNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings but is unlikely to drive major price movement.

02

Market read

A routine insider sale with modest size; relevant for investors monitoring insider activity but not a catalyst for significant trading.

03

What to watch

Potential upcoming regulatory or product developments not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: filing today

Background

Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$RMDNeutralMedium confidence
Context

CEO Michael J. Farrell sold 4,993 shares of ResMed for $1.175M via a 10b5‑1 plan, reducing his holdings to 479,803 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

A $1.2M sale by the CEO is material enough to be noted, yet the size is modest relative to ResMed's market cap, so any price effect is expected to be limited.

Market effects

Sector

Minimal impact on the broader medical device sector; insider sales are routine.

Regional

No significant regional effect.

Global

Limited to ResMed investors.

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals and merely a portfolio rebalancing.

Key entities

  • Company
    ResMed Inc.

    Medical device manufacturer listed on NYSE under ticker RMD.

  • Executive
    Michael J. Farrell

    Chairman and CEO of ResMed who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RMD insider trading history →

Related articles

$RMDMedAI 8/10

What Sent ResMed Stock Lower?

ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.

finance.yahoo.com
$RMDMed

ResMed (RMD) Q1 2027 Earnings Call Transcript

ResMed (RMD) reported Q1 2027 earnings, highlighting innovation in sleep health products, including new bilevel devices and fabric masks. The company saw a 6% increase in therapy adherence with fabric masks and 4.3% with AI-driven Smart Comfort. ResMed also improved gross margins and expanded U.S. manufacturing. The myAir app, with 13M+ downloads, enhances patient engagement and compliance.

finance.yahoo.com
$RMDMedAI 8/10

What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed (RMD) reported Q1 residential care software revenue declined 7% but increased 5% on a constant-currency basis. The company launched new devices and digital tools, with management highlighting growth in patient engagement. Non-GAAP gross margin rose to 62.5%. ResMed maintained its fiscal 2027 guidance, expecting 5-7% core revenue growth and EPS of $12-$12.25. The company is expanding U.S. manufacturing and discontinuing Astral ventilators.

finance.yahoo.com
$RMDHighAI 8/10

ResMed 3Q 2026: Revenue $1.41B, EPS $2.92— 10-Q Summary

ResMed reported 3Q 2026 revenue of $1.41B, up 5.9% YoY, with net income rising 20% to $418.41M and EPS increasing 23.2% to $2.92. Sleep and Breathing Health revenue grew 8%, while Residential software revenue declined 7% post-MatrixCare sale. The company completed the MatrixCare divestiture and expects input-cost inflation to persist through fiscal 2027.

tradingview.com